Key Takeaways

  • Clover Health (NASDAQ:CLOV) increased 11.35% during premarket dealings on October 9, 2026 on a displayed price of USD 4.58 and a market Capitalization of approximately USD 2.43 billion.
  • No Clover-specific disclosure was identified for October 8 or 9; the screener tags the move as news, and the likeliest backdrop is the October 8 CMS star ratings statement that moved Humana and Alignment.
  • Second-quarter 2026 Revenue increased 55.6% to USD 743.2 million and Net Income was USD 28.0 million against a loss of USD 10.6 million a year earlier, per the Business statement of August 5.
  • Full-year guidance was raised to revenue of USD 2.92 billion to USD 3.00 billion and adjusted EBITDA of USD 70 million to USD 85 million, with membership of 157,309 at June 30.

Factors Behind Clover’s Share-Price Move

Clover Health (NASDAQ:CLOV) was indicated to be up 11.35% in the October 9, 2026 premarket session on the screener, on a displayed price of USD 4.58 and pre-market Volume of 40,045 shares. The screener tags the catalyst as news, but a search located no business statement, filing or analyst note dated October 8 or 9, so the cause is unconfirmed. The most relevant backdrop is the Centers for Medicare and Medicaid Services 2027 Star Ratings, released October 8, 2026, which lifted Humana's largest contract and cut Alignment Healthcare's. Reports reviewed did not demonstrate Clover's own contract ratings, so any link between those ratings and this move is an inference, not a finding.

Results and Guidance Behind the Stock

Clover's last report, on August 5, 2026, indicated second-quarter revenue of USD 743.2 million, up 55.6% from USD 477.6 million, and net income of USD 28.0 million against a net loss of USD 10.6 million a year earlier. Adjusted EBITDA increased 139.2% to USD 40.9 million. Insurance membership reached 157,309 at June 30 from 106,323 a year earlier. Management raised full-year guidance to revenue of USD 2.92 billion to USD 3.00 billion, adjusted EBITDA of USD 70 million to USD 85 million and GAAP net income of USD 20 million to USD 35 million. The statement pointed to the flexibility of a 4.5 star payment year in its 2027 outlook.

Principal Risks and Upcoming Developments

Medicare Advantage margins depend on medical costs, risk adjustment and star ratings, and the sector just demonstrated how one rating decision can move shares by 15% to 23% in either direction, as Humana and Alignment did. Clover Health (NASDAQ:CLOV) lists its ability to maintain or improve star ratings among its risk drivers. Rapid membership growth can also strain claims forecasting, and a 4.5 star payment year can change in later cycles. Investors may wish to read Clover's contract-level ratings when available, watch the next Quarterly Report and compare cost trends with larger peers. A premarket gain on 40,045 shares is a thin quote that may reverse at the open.

Current Assessment

Clover Health (NASDAQ:CLOV) is trading higher in premarket, but no company announcement could be located, so the cause is unconfirmed; the likeliest context is sector attention after the October 8 star ratings statement, which is an inference. The fundamentals look robust on paper: second-quarter revenue up 55.6%, favorable net income and a raised outlook. The available evidence, viewed as a whole, indicates that this is a sympathy or momentum move on thin volume rather than an issuer-specific event. The next items to monitor are Clover's own contract ratings, any filing and the next Earnings report.